SCHEMBL20580237

SCHEMBL20580237

CN(C)C(=O)N1OCC[C@H]1c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 9/20 0.41
KIF11 P52732 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
NPSR1 Q6W5P4 1/20 0.36
P2RX4 Q99571 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873176 1.00 RIPK1 (0.41) RIPK1KIF11CHRNB2CHRNB4CHRNA3
SCHEMBL22210929 0.83 POLB (0.45) RIPK1KIF11CHRNB2CHRNB4CHRNA3
SCHEMBL22232765 0.82 RIPK1 (0.43) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL18921305 0.82 RIPK1 (0.43) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20580690 0.82 RIPK1 (0.50) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20580272 0.81 RIPK1 (0.46) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL18921351 0.81 RIPK1 (0.46) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL18921500 0.81 RIPK1 (0.46) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL26089736 0.80 RIPK1 (0.41) RIPK1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20580293 0.79 RIPK1 (0.58) RIPK1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108602809-B Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) 戴纳立制药公司 2022-09-30 CN disclosed
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) DENALI THERAPEUTICS INC. (US) 2020-07-14 US disclosed
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) DENALI THERAPEUTICS INC. (US) 2020-07-14 US disclosed
US-20180353480-A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) APTUIT (VERONA) S.R.L. (IT) 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353480-A1 ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) RIPK1, RIPK2, RIPK3 RIPK1 1/4885KIF11 4598/4885CHRNB2 2282/4885
US-10709692-B2 Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) RIPK1, RIPK2, RIPK3 RIPK1 1/4885KIF11 4598/4885CHRNB2 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.